Literature DB >> 29295821

Anaplastic thyroid carcinoma: review of treatment protocols.

Vera Tiedje1, Martin Stuschke2, Frank Weber3, Henning Dralle3, Laura Moss4, Dagmar Führer5.   

Abstract

Anaplastic thyroid carcinoma (ATC) is an orphan disease and in most patients fatal. So far no established treatment is available that prolongs survival. Several large retrospective studies have identified negative prognostic markers, analyzed efficacy of multimodal approaches such as radiotherapy with and without concurrent chemotherapy and chemotherapy protocols. Recently, single case reports have suggested some effectiveness of newer therapies targeting single somatic alterations in ATC. Overall, the conclusions that can be drawn from published retrospective studies and the scarce prospective approaches is that new treatment protocols should be developed including surgery, radiotherapy, chemotherapy and targeted therapy approaches and combinational therapy with immunotherapies. These protocols then need to be evaluated prospectively to improve ATC patients' outcome in routine care.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  anaplastic thyroid carcinoma; radiotherapy; targeted therapy; treatment protocol

Mesh:

Year:  2018        PMID: 29295821     DOI: 10.1530/ERC-17-0435

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  36 in total

1.  Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.

Authors:  Silvia Cantara; Eugenio Bertelli; Rossella Occhini; Marì Regoli; Lucia Brilli; Furio Pacini; Maria Grazia Castagna; Paolo Toti
Journal:  Endocrine       Date:  2019-02-14       Impact factor: 3.633

2.  Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.

Authors:  Haruhiko Yamazaki; Tomoyuki Yokose; Hiroyuki Hayashi; Hiroyuki Iwasaki; Sachie Osanai; Nobuyasu Suganuma; Hirotaka Nakayama; Katsuhiko Masudo; Yasushi Rino; Munetaka Masuda
Journal:  Eur J Clin Pharmacol       Date:  2020-02-07       Impact factor: 2.953

3.  Multimodal treatment based on thyroidectomy improves survival in patients with metastatic anaplastic thyroid carcinoma: a SEER analysis from 1998 to 2015.

Authors:  Tao Song; Long Chen; Haibo Zhang; Yanwei Lu; Kun Yu; Wenming Zhan; Min Fang
Journal:  Gland Surg       Date:  2020-10

4.  Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival.

Authors:  Sabine Wächter; C Vorländer; J Schabram; I Mintziras; I Fülber; J Manoharan; K Holzer; D K Bartsch; E Maurer
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-14       Impact factor: 2.503

5.  Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer.

Authors:  Woo Kyung Lee; Won Gu Kim; Laura Fozzatti; Sunmi Park; Li Zhao; Mark C Willingham; David Lonard; Bert W O'Malley; Sheue-Yann Cheng
Journal:  Endocr Relat Cancer       Date:  2020-04       Impact factor: 5.678

6.  Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.

Authors:  Lisha Gou; Huawei Zou; Beibei Li
Journal:  Cancer Biol Ther       Date:  2019-09-10       Impact factor: 4.742

Review 7.  [Genetics of thyroid nodules and thyroid carcinoma].

Authors:  D Führer
Journal:  Internist (Berl)       Date:  2018-07       Impact factor: 0.743

8.  Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma.

Authors:  Haruhiko Yamazaki; Hiroyuki Iwasaki; Nobuyasu Suganuma; Soji Toda; Katsuhiko Masudo; Hirotaka Nakayama; Yasushi Rino; Munetaka Masuda
Journal:  Gland Surg       Date:  2021-03

9.  V600EBRAF Inhibition Induces Cytoprotective Autophagy through AMPK in Thyroid Cancer Cells.

Authors:  Eva Jiménez-Mora; Beatriz Gallego; Sergio Díaz-Gago; Marina Lasa; Pablo Baquero; Antonio Chiloeches
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

10.  Emerging roles of circUBAP2 targeting miR-370-3p in proliferation, apoptosis, and invasion of papillary thyroid cancer cells.

Authors:  Hui Xiong; Jinsong Yu; Guangwei Jia; Yang Su; Jianliang Zhang; Qiu Xu; Xiaoxiong Sun
Journal:  Hum Cell       Date:  2021-08-03       Impact factor: 4.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.